Surrozen, Inc. (NASDAQ:SRZNW) Short Interest Down 49.3% in December

Surrozen, Inc. (NASDAQ:SRZNW) was the target of a significant decline in short interest in December. As of December 15th, there was short interest totaling 38,172 shares, a decline of 49.3% from the November 30th total of 75,217 shares. Based on an average daily trading volume, of 16,440 shares, the days-to-cover ratio is currently 2.3 days. Based on an average daily trading volume, of 16,440 shares, the days-to-cover ratio is currently 2.3 days.

Surrozen Stock Performance

Shares of NASDAQ SRZNW opened at $0.02 on Friday. The stock’s 50-day simple moving average is $0.02 and its two-hundred day simple moving average is $0.02. Surrozen has a twelve month low of $0.00 and a twelve month high of $0.09.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on the discovery and development of novel therapeutics that harness the Wnt signaling pathway. The company employs a proprietary “surrogate agonist” platform to engineer bispecific antibodies that mimic natural Wnt ligands by concurrently engaging Frizzled receptors and LRP5/6 co-receptors. This approach is designed to promote tissue regeneration and modulate cellular pathways implicated in fibrosis and oncology.

Surrozen’s lead program is advancing in fibrotic disease, where restoring proper Wnt signaling may support the repair of damaged tissues in conditions such as idiopathic pulmonary fibrosis.